TVTX
What one share of Travere Therapeutics holds
Pharmaceutical Preparations
We are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Our approach centers on advancing our innovative pipeline with multiple late-stage clinical programs targeting rare diseases with significant unmet medical needs.
Travere Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $6.48 |
|---|---|
| Profit | −$0.48 |
| Cash and investments | $1.25 |
| Book value | $0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $3.49 | −$1.29 | $0.04 | −$0.13 | — | $8.12 |
| 2017 | $4.00 | −$1.54 | $0.02 | $0.17 | — | $7.44 |
| 2018 | $4.06 | −$2.54 | $0.02 | −$0.64 | — | $7.69 |
| 2019 | $4.14 | −$3.46 | $0.00 | −$1.38 | — | $5.13 |
| 2020 | $4.17 | −$3.56 | $0.14 | −$1.04 | — | $4.04 |
| 2021 | $2.20 | −$3.01 | $0.09 | −$0.33 | — | $4.83 |
| 2022 | $1.72 | −$4.37 | $0.00 | −$2.92 | — | $0.67 |
| 2023 | $1.96 | −$1.50 | $0.01 | −$3.78 | — | $2.66 |
| 2024 | $2.96 | −$4.08 | — | −$3.01 | — | $0.68 |
| 2025 | $5.50 | −$0.29 | — | $0.42 | — | $1.26 |